# Corbus (CRBP) — News

CRBP · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/crbp/news

## Recent headlines

- [PTC Industries - Raises 18 bln rupees through qualified institutions placement](https://www.ainvest.com/news/ptc-industries-raises-18-bln-rupees-qualified-institutions-placement-2610) — AInvest Wire, Oct 13, 2026
  PTC Industries has raised ₹18 billion through a qualified institutional placement (QIP), a move aimed at strengthening its capital base and supporting ongoing expansion initiatives. The placement was oversubscribed, reflecting strong investor confidence in the company’s strategic direction and…
- [Cannabis stocks fell in intraday trading, with GNLN down 9.43%, SNDL falling 2.38% and CRBP sliding 1.03%.](https://www.ainvest.com/news/cannabis-stocks-fell-intraday-trading-gnln-9-43-sndl-falling-2-38-crbp-sliding-1-03-2610-10) — AInvest Wire, Oct 6, 2026
  Cannabis-related equities experienced a decline during intraday trading on October 6, 2026. Among the most notable performers, GrowLife Inc. (GNLN) dropped 9.43%, while Sundial Growers Inc. (SNDL) fell 2.38%. Cannabis RB Partners (CRBP) also saw a modest decline of 1.03% [1]. The sector-wide…
- [Corbus Pharmaceuticals announces first patient dosed in tempo-1 registrational study of CRB-701 in patients with 2L+ oropharyngeal cancer](https://www.ainvest.com/news/corbus-pharmaceuticals-announces-patient-dosed-tempo-1-registrational-study-crb-701-patients-2l-oropharyngeal-cancer-2609) — AInvest Wire, Sep 29, 2026
- [Corbus Pharmaceuticals Holdings, - CRB-913 treatment discontinuations due to adverse events range from 3.1% to 13.1%](https://www.ainvest.com/news/corbus-pharmaceuticals-holdings-crb-913-treatment-discontinuations-due-adverse-events-range-3-1-13-1-2609) — AInvest Wire, Sep 14, 2026
- [Corbus Pharmaceuticals Holdings, - expects to initiate phase 2 monotherapy study for CRB-913 in H1 2027](https://www.ainvest.com/news/corbus-pharmaceuticals-holdings-expects-initiate-phase-2-monotherapy-study-crb-913-h1-2027-2609) — AInvest Wire, Sep 14, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).